Ara290 Dsip VIP Dihexa Epitalon Glutathione Ghk-Cu Kpv Ll37 Melanotan2 Nad+ Oxytocin Pnc27 Selank Semax Ss31 Snap-8 with High Purity
26 Inquiries
67727-97-3
99%
qingdao
JF
vials
2026-03-04
Weight Loss Peptide,Reta,Tirz,Sema,5 Amino 1mq,Cosmetic raw material,API,SLU-PP-332
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceLys-Pro-Val is an oligopeptide.Basic Info
-
Product Name:
ALPHA-MSH (11-13) ACETATE SALT
Other Name:H-LYS-PRO-VAL-OH ACETATE SALT;H-LYS-PRO-VAL-OH ACOH;ALPHA-MSH (11-13);ALPHA-MSH (11-13) ACETATE SALT;msh(11-13;.alpha.-MSH (11-13) (free acid);H-Lys-Pro-Val-OH;alpha-Msh (11-13) (free acid) acetate salt
CAS No.:67727-97-3
Molecular Formula:C18H34N4O6
InChIKeys:YSPZCHGIWAQVKQ-AVGNSLFASA-N
Molecular Weight:402.49
Exact Mass:342.226705
Categories:
Characteristics-
PSA:
139
Storage Conditions:-15°C
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Weight Loss Peptide,Reta,Tirz,Sema,5 Amino 1mq,Cosmetic raw material,API,SLU-PP-332
-
Location:
Unit D01,3/F., Wong King Industrial Building,No.2 Tai Yau Street, Kowloon
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7 days
-
Total Annual Revenue:
$50 million-$100 million
-
Total Employees:
51-100
-
Year of Establishment:
2012
-
-
Inquiry History26 Inquiries
Country Product Purchase Quantity Date Posted
Brazil
67727-97-3
10 MT Apr 30, 2026
United States
Klow blends 80mg 10 vials
10 MG Feb 12, 2026
United States
KPV
0.1 G Jul 13, 2026
Canada
Kpv
10 G May 9, 2026
United States
kpv
1 KG May 8, 2026
Canada
KPV | US Warehouse | Cosmetic Peptides | 99% Purity | 5mg 10mg Vials | Lyophilized Powder
10 MG Apr 16, 2026
United States
KLOW
1 MT Apr 15, 2026
Brazil
kpv
10 MT Mar 12, 2026
United States
KPV
10 MG Feb 28, 2026
United States
Klow80
10 MT Jul 29, 2026
United States
Klow80
1 MT May 23, 2026
Canada
KPV
1 KG Nov 24, 2025
United States
KPV
50 MG Nov 10, 2025
United States
KlOW
20 Aug 9, 2026
Netherlands
klow
10 MT Jul 9, 2026
United States
Klow
800 MG Jul 3, 2026
United States
KPV
2 KG Jun 19, 2026
Portugal
KLOW
80 MG May 28, 2026
United States
KPV (KLOW)
100 MT May 18, 2026
United States
Glow blend
10 MT Apr 4, 2026 Post an enquiry for this product
More from this Seller
-
-
-
Natural Nuciferine CAS No.475-83-2 raw powder with high purity 98% and good price
Pharmaceutical Grade / 99%
$2/G FOB
-
-
-
-
Adipotide 2mg Peptide for Weight Loss Peptides Fttp
Pharmaceutical Grade / 99%
$100-130/G FOB
-
-
-
-
Top Quality 99% SLU-PP-915 Raw Material Powder CAS 2285432-92-8 slu-pp-915
Pharmaceutical Grade / 99%
$22/G FOB
-
-
-
-
Top Quality EPA+DHA Fish Oil CAS 8016-13-5 Raw Material with OEM/ODM
Food Grade / 99%
-
-
-
-
Manufacturer Direct Supply High Purity Urolithin A Powder CAS 1143-70-0
Pharmaceutical Grade / 99%
-
-
-
-
High Purity Raw Material Supplier KY19382 Powder CAS 2226664-93-1
Pharmaceutical Grade / 99%
-